Fardin Djafari, MD
Cardiovascular Disease · Wichita Falls, TXNPI 1043298391
Payments from drug & device makers
Across 336 payments — averaging $19.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$1K
- Novartis$944
- Boehringer Ingelheim$691
- E.r. Squibb & Sons, L.L.C.$630
- Pfizer$492
- Johnson & Johnson$465
- plus $2K from 28 others
What the payments were for
- Food & beverage$6,692100%
- Education$250%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abiomed | 45 | $1,027 |
| Novartis | 48 | $944 |
| Boehringer Ingelheim | 27 | $691 |
| E.r. Squibb & Sons, L.L.C. | 62 | $630 |
| Pfizer | 29 | $492 |
| Johnson & Johnson | 27 | $465 |
| Merck | 20 | $389 |
| Edwards Lifesciences | 5 | $241 |
| Amgen | 13 | $213 |
| Abbott | 6 | $205 |
| AstraZeneca | 3 | $136 |
| Scpharmaceuticals Inc. | 1 | $133 |
| Astellas Pharma US Inc | 7 | $127 |
| Heartflow, Inc. | 1 | $126 |
| Boston Scientific | 4 | $109 |
| Philips North America LLC | 2 | $108 |
| Kiniksa Pharmaceuticals International, PLC | 4 | $65 |
| Sanofi-aventis U.S. LLC | 4 | $63 |
| Regeneron Healthcare Solutions, Inc. | 4 | $63 |
| Bayer | 3 | $60 |
| Amarin Pharma, Inc. | 3 | $58 |
| Medtronic | 1 | $53 |
| Chiesi USA, Inc. | 2 | $43 |
| Gilead | 3 | $42 |
| Inari Medical, Inc. | 2 | $39 |
| Cvrx, Inc. | 1 | $33 |
| Inspire Medical Systems, Inc. | 2 | $29 |
| Spectrawave, Inc | 1 | $23 |
| Esperion Therapeutics, Inc. | 1 | $21 |
| Novo Nordisk | 1 | $21 |
| Baxter Healthcare | 1 | $20 |
| Vifor Pharma, Inc. | 1 | $17 |
| Shockwave Medical, Inc | 1 | $14 |
| Atricure, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,716 in reported general payments places this provider in the 60th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 704 | $683,309 |
| XareltoRivaroxaban | 206 | $192,645 |
| Repatha SureclickEvolocumab | 58 | $51,077 |
| JardianceEmpagliflozin | 37 | $43,463 |
| BrilintaTicagrelor | 20 | $16,285 |
| Metoprolol Succinate | 1,099 | $15,838 |
| EntrestoSacubitril/Valsartan | 20 | $14,017 |
| Praluent PenAlirocumab | 11 | $13,654 |
| Rosuvastatin Calcium | 374 | $7,409 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 27 | $5,448 |
| Atorvastatin Calcium | 476 | $4,926 |
| Nebivolol Hcl | 78 | $4,543 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 139 | $3,655 |
| Amlodipine Besylate | 519 | $3,500 |
| Spironolactone | 395 | $3,157 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $492 | $683,309704 claims |
| Johnson & JohnsonXarelto | $465 | $192,645206 claims |
| Boehringer IngelheimJardiance | $691 | $43,46337 claims |
| AstraZenecaBrilinta | $136 | $16,28520 claims |
| NovartisEntresto | $944 | $14,01720 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in Wichita Falls
- Andre DesireWichita Falls$521K
- Ramin Farzaneh-FarDallas$17.1M
- Jeffrey GladdenDallas$15.8M
- Ann NavarDallas$14.5M
- David BrabhamAmarillo$11.5M
- Justin GrodinDallas$6.2M
- Christie BallantyneHouston$4.6M
- Syed NaqviHouston$3.6M
- Faisal WahidMcKinney$3.4M
- James FeldmanHouston$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.